Simplify Logo

Full-Time

Software Engineer – Senior / Staff / Principal

Confirmed live in the last 24 hours

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

AI & Machine Learning
Biotechnology

Senior, Expert

Burlingame, CA, USA

Hybrid position in Burlingame, CA.

Category
Backend Engineering
Full-Stack Engineering
Software Engineering
Requirements
  • Experienced writing production code and driving projects to completion
  • Comfortable working across all levels of the software stack, from front-end interfaces to backend features to managing infrastructure
Responsibilities
  • Build and expand on tools for visualizing molecules and proteins, analyzing machine learning models, and managing complex chemical workflows
  • Work closely with machine learning engineers and medicinal chemists to develop and productionize new computational methods for molecular property prediction
  • Help scale our data infrastructure to handle billions of datapoints and thousands of parallel deep learning and molecular dynamics jobs

Genesis Therapeutics focuses on accelerating the development of new medicines using artificial intelligence in the drug discovery sector. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables the exploration of new chemical spaces and the discovery of novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide its AI-driven drug discovery services. The company generates revenue through upfront payments and potential future earnings based on the success of the drugs developed through its platform. Genesis Therapeutics aims to transform the drug discovery process and bring critical new medicines to market.

Company Stage

Series B

Total Funding

$256.1M

Headquarters

Burlingame, California

Founded

2019

Growth & Insights
Headcount

6 month growth

23%

1 year growth

51%

2 year growth

156%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recognition as a 'Fierce 15' company and one of America's most promising AI companies highlights Genesis Therapeutics' industry leadership and innovation.
  • The $200M Series B funding will enable the company to advance its AI-enabled pipeline into clinical development, potentially leading to groundbreaking new treatments.
  • Partnerships with industry giants like NVIDIA and Eli Lilly provide substantial opportunities for growth and collaboration.

What critics are saying

  • The highly competitive biotech and AI-driven drug discovery sectors may pose challenges in maintaining a unique market position.
  • Dependence on strategic partnerships and funding rounds could impact financial stability if future deals or investments do not materialize.

What makes Genesis Therapeutics unique

  • Genesis Therapeutics leverages a unique combination of 3D spatial graph modeling and advanced molecular simulation, setting it apart from traditional drug discovery methods.
  • Their AI platform, GEMS, is capable of generating novel drug-like molecules and making rapid, accurate predictions for challenging targets, which is a significant competitive advantage.
  • Strategic partnerships with major pharmaceutical companies like Eli Lilly and significant funding rounds, including a $200M Series B, underscore their strong market position.

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program